Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma

Cai,Yi-Ran; Zhang,Hai-Qing; Zhang,Zong-De; Mu,Jing; Li,Zi-Hui

doi:10.3892/ol.2010.229

Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma

Authors:
- Yi-Ran Cai
- Hai-Qing Zhang
- Zong-De Zhang
- Jing Mu
- Zi-Hui Li
View Affiliations

Affiliations: Department of Pathology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Beijing 101149, P.R. China, Laboratory of Molecular Biology for Mycobacteria, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, P.R. China
Published online on: December 23, 2010 https://doi.org/10.3892/ol.2010.229
Pages: 257-264

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung carcinoma is a leading cause of cancer-related death. Amplification of the two oncogenes MET and SOX2 is frequently encountered in non-small-cell lung carcinoma. This study aimed to use real-time quantitative PCR to assess the correlation of MET and SOX2 amplification with clinicopathological factors. This study was conducted using 115 tissue samples including 57 squamous cell carcinomas (SCCs), 50 adenocarcinomas (ADCs) and 8 adenosquamous carcinomas (ADSCs). A total of 67 patients (58.3%) had a history of smoking. Our results showed that the frequency of MET amplification in SCCs was significantly higher compared to ADCs (χ2=8.0, P=0.005). SOX2 showed a markedly preferential amplification in SCCs compared to ADCs in the smoking group cases (P=0.014). Lymph node invasion correlated with MET amplification in SCCs marginally more significantly compared to ADCs (P=0.02). The amplified MET occurred more frequently in SCCs compared to ADCs correlated to tumor dimension at a small scale (<5 cm) (P=0.01). No significant difference in SOX2 amplification was found with regards to lymph node metastasis or tumor dimension. SOX2 and MET amplifications were not associated with gender or age. However, MET amplification in SCCs among patients younger than 64 years of age was higher compared to ADCs and ADSCs (P=0.03). Among ADSCs, MET was not amplified among patients who had never been smokers or were younger than 64 years of age. Neither MET nor SOX2 were amplified in tumors with dimensions <5 cm and without lymph node invasion. Findings of this study showed that MET and SOX2 amplifications are more common in the SCCs of smokers. Moreover, MET amplification is intrinsic in SCCs particularly among smokers, with regards to tumor growth, lymph node invasion and negative correlation to SOX2 amplification. The incidence of discrepancy in the amplifications of MET and SOX2 in SCCs and ADCs suggests that the MET and SOX2 genes play different roles in SCC and ADC tumorigenesis, respectively, particularly among smokers.

View Figures

View References

1	Travis WD, Brambilla E and Muller-Hermelink HK: World Health Organization Classification of Tumours, Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon: 2004
2	Laird AD and Cherrington JM: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs. 12:51–64. 2003. View Article : Google Scholar : PubMed/NCBI
3	Maulik G, Kijima T and Salgia R: Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 74:113–125. 2003.PubMed/NCBI
4	Lamorte L and Park M: The receptor tyrosine kinases: role in cancer progression. Surg Oncol Clin N Am. 10:271–288. 2001.PubMed/NCBI
5	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246. 2003.
6	Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
7	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
8	Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
9	Naldini L, Weidner KM, Vigna E, et al: Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10:2867–2878. 1991.PubMed/NCBI
10	Bottaro DP, Rubin JS, Faletto DL, et al: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 251:802–804. 1991. View Article : Google Scholar : PubMed/NCBI
11	Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 4:915–925. 2003. View Article : Google Scholar : PubMed/NCBI
12	Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT and Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 13:41–59. 2002. View Article : Google Scholar : PubMed/NCBI
13	Cooper CS, Park M, Blair DG, et al: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 311:29–33. 1984. View Article : Google Scholar : PubMed/NCBI
14	Chen JT, Lin TS, Chow KC, et al: Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol. 34:264–273. 2006. View Article : Google Scholar : PubMed/NCBI
15	Nakamura Y, Niki T, Goto A, et al: c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 98:1006–1013. 2007. View Article : Google Scholar : PubMed/NCBI
16	Tsao MS, Liu N, Chen JR, et al: Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer. 20:1–16. 1998. View Article : Google Scholar : PubMed/NCBI
17	Beau-Faller M, Gaub MP, Schneider A, et al: Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression. Eur J Cancer. 39:2538–2547. 2003. View Article : Google Scholar : PubMed/NCBI
18	Smolen GA, Sordella R, Muir B, et al: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA. 103:2316–2321. 2006. View Article : Google Scholar : PubMed/NCBI
19	Miller CT, Lin L, Casper AM, et al: Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene. 25:409–418. 2006.PubMed/NCBI
20	Que J, Luo X, Schwartz RJ and Hogan BL: Multiple roles for Sox2 in the developing and adult mouse trachea. Development. 136:1899–1907. 2009. View Article : Google Scholar : PubMed/NCBI
21	Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D and Rottier R: Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol. 317:296–309. 2008. View Article : Google Scholar : PubMed/NCBI
22	Park KS, Wells JM, Zorn AM, et al: Transdifferentiation of ciliated cells during repair of the respiratory epithelium. Am J Respir Cell Mol Biol. 34:151–157. 2006. View Article : Google Scholar : PubMed/NCBI
23	Tsukamoto T, Mizoshita T, Mihara M, et al: Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathology. 46:649–658. 2005. View Article : Google Scholar : PubMed/NCBI
24	Li XL, Eishi Y, Bai YQ, et al: Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol. 24:257–263. 2004.PubMed/NCBI
25	Hussenet T, Dali S, Exinger J, et al: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 5:e89602010. View Article : Google Scholar : PubMed/NCBI
26	Ebright MI, Zakowski MF, Martin J, et al: Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg. 74:1640–1647. 2002. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ, Flood SJ, Marmaro J, Giusti W and Deetz K: Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4:357–362. 1995. View Article : Google Scholar : PubMed/NCBI
28	Higuchi R, Fockler C, Dollinger G and Watson R: Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (NY). 11:1026–1030. 1993. View Article : Google Scholar : PubMed/NCBI
29	Holland PM, Abramson RD, Watson R and Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA. 88:7276–7280. 1991.
30	Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R and Vidaud M: Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer. 78:661–666. 1998. View Article : Google Scholar : PubMed/NCBI
31	Beau-Faller M, Ruppert AM, Voegeli AC, et al: MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol. 3:331–339. 2008. View Article : Google Scholar : PubMed/NCBI
32	Turke AB, Zejnullahu K, Wu YL, et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17:77–88. 2010. View Article : Google Scholar : PubMed/NCBI
33	Maestrini E, Tamagnone L, Longati P, et al: A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc Natl Acad Sci USA. 93:674–678. 1996. View Article : Google Scholar : PubMed/NCBI
34	Comoglio PM and Boccaccio C: The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells. 1:347–354. 1996. View Article : Google Scholar : PubMed/NCBI
35	De Herdt MJ and Baatenburg de Jong RJ: HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci. 13:2516–2526. 2008.PubMed/NCBI
36	Go H, Jeon YK, Park HJ, Sung SW, Seo JW and Chung DH: High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 5:305–313. 2010. View Article : Google Scholar : PubMed/NCBI
37	Okuda K, Sasaki H, Yukiue H, Yano M and Fujii Y: Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 99:2280–2285. 2008. View Article : Google Scholar : PubMed/NCBI
38	Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
39	Cappuzzo F, Marchetti A, Skokan M, et al: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 27:1667–1674. 2009. View Article : Google Scholar : PubMed/NCBI
40	Masui S, Nakatake Y, Toyooka Y, et al: Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol. 9:625–635. 2007. View Article : Google Scholar : PubMed/NCBI
41	Wicha MS, Liu S and Dontu G: Cancer stem cells: an old idea--a paradigm shift. Cancer Res. 66:1883–1890. 2006. View Article : Google Scholar : PubMed/NCBI
42	Ben-Porath I, Thomson MW, Carey VJ, et al: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 40:499–507. 2008. View Article : Google Scholar : PubMed/NCBI
43	Chen Y, Shi L, Zhang L, et al: The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem. 283:17969–17978. 2008. View Article : Google Scholar : PubMed/NCBI
44	Biermann K, Heukamp LC, Steger K, et al: Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors. Cancer Genomics Proteomics. 4:359–367. 2007.PubMed/NCBI
45	Sholl LM, Long KB and Hornick JL: Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry. 18:55–61. 2010. View Article : Google Scholar : PubMed/NCBI
46	Hussenet T and du Manoir S: SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle. 9:1480–1486. 2010. View Article : Google Scholar : PubMed/NCBI
47	Bass AJ, Watanabe H, Mermel CH, et al: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009. View Article : Google Scholar : PubMed/NCBI
48	Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, et al: DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer. 22:79–82. 1998. View Article : Google Scholar : PubMed/NCBI
49	Sholl LM, Barletta JA, Yeap BY, Chirieac LR and Hornick JL: Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol. 34:1193–1198. 2010. View Article : Google Scholar : PubMed/NCBI
50	McCaughan F, Pole JC, Bankier AT, et al: Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med. 182:83–91. 2010. View Article : Google Scholar : PubMed/NCBI
51	Bastide K, Ugolin N, Levalois C, Bernaudin JF and Chevillard S: Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? Lung Cancer. 68:1–9. 2010. View Article : Google Scholar : PubMed/NCBI